Bryan Johnson Hyperbaric Chamber: Experiment, Evidence & Safety Insights

Bryan Johnson uses a hard-shell hyperbaric chamber at 2.0 ATA with 100% oxygen as part of his Blueprint longevity protocol, which he has said costs over $2 million a year to run. He treats it as one variable among dozens, tracking any change against a monthly biomarker baseline. Here is the equipment he uses, the reasoning behind it, and what the clinical evidence actually says about HBOT and aging.

Johnson has spoken publicly about adding a hyperbaric chamber to his routine in pursuit of slower biological aging. The useful question is not whether a wealthy founder uses it, but whether the science behind that choice holds up. This article separates the two.

What Hyperbaric Chamber Does Bryan Johnson Use?

Johnson uses a clinical-grade hard-shell hyperbaric chamber at his home, running sessions at 2.0 ATA (atmospheres absolute) with 100% oxygen, multiple times per week. He views it as a possible tool for slowing or reversing cellular aging, citing research on telomere length and cerebral blood flow. HBOT sits inside a Blueprint stack that also includes measured diet, sleep timing, exercise protocols, and dozens of medications and supplements.

That stack is the catch. Johnson is a single person running an uncontrolled self-experiment. His outcomes, whatever they are, cannot be separated from the dozens of other interventions he uses at the same time. HBOT may be doing something, nothing, or something harmful. There is no way to know from one person’s n=1 experience. The table below shows how his setup maps onto the actual research protocol.

Is There Real Evidence HBOT Slows Aging?

The research on HBOT for cognitive aging is more developed than the biohacking narrative suggests, but it remains preliminary and comes almost entirely from one group. The most relevant work is from a team led by Prof. Shai Efrati at the Sagol Center for Hyperbaric Medicine (Shamir Medical Center, affiliated with Tel Aviv University).

A 2020 randomized controlled trial enrolled 63 healthy adults over age 64 and assigned them to either 60 HBOT sessions or a control group.¹ The HBOT group received 90-minute sessions at 2.0 ATA with air breaks every 20 minutes. At the end of the 3-month protocol, the HBOT group showed significant improvements in global cognitive function (p=0.0017) with large effect sizes for attention (0.745) and information processing speed (0.788). Perfusion MRI confirmed increased cerebral blood flow to prefrontal and parietal regions, consistent with the proposed mechanism of angiogenesis and improved perfusion.⁵

A separate trial from the same group, published in 2020, measured telomere length in 35 healthy adults over 64 before, during, and after 60 HBOT sessions.² Telomere length increased by more than 20 percent across multiple immune cell types. B cells showed the largest change, at 29 percent by session 60 (p=0.0001). Senescent T helper cells decreased by 37.3 percent (p<0.0001). These are recognized biomarkers of cellular aging, though they are surrogate markers, not measures of lifespan.

A 2024 RCT from the same group found that 60 sessions of HBOT improved VO2max by 1.91 ml/kg/min (net effect size 0.455, p=0.0034) and significantly increased cardiac perfusion in older adults.³ That gives Johnson’s interest in HBOT for physical performance some grounding in peer-reviewed data, and it is part of why HBOT draws attention from competitors, a topic we cover in our guide to hyperbaric oxygen for athletes.

These results are promising and also preliminary. All of the longevity and cognitive data comes from a single research group, the telomere study had no sham control, and independent replication has not been published. The FDA has not cleared HBOT for anti-aging or cognitive enhancement. These are off-label uses under exploratory study, and no human trial has shown that HBOT extends lifespan. For the full data picture, see our breakdown of the HBOT anti-aging telomere data and our overview of HBOT for longevity and performance.

Celebrity Use Is Not Evidence

The attention around Johnson’s HBOT use has driven a wave of consumer interest, and that deserves an honest caveat. Johnson is not a clinical researcher. His experience is not a controlled study. The fact that a wealthy entrepreneur uses a technology is not, by itself, evidence that the technology works. The same applies to other high-profile users, from athletes to entertainers, such as the widely discussed LeBron James hyperbaric chamber setup.

Johnson’s biomarkers may improve while he uses HBOT. They may improve because of something else entirely, or because of regression to the mean, placebo effect, or statistical noise. Without a sham-controlled trial, no one, including Johnson, can attribute a specific outcome to HBOT. This is not a reason to dismiss HBOT. The clinical evidence above is genuinely interesting. It is a reason to read celebrity endorsements as marketing context, not scientific data.

Is HBOT Safe for Longevity Use?

HBOT has a well-established safety profile when delivered in properly maintained hard chambers under clinical supervision, but longevity use is off-label and carries the standard hyperbaric risks. The FDA has cleared HBOT for a defined set of indications including decompression sickness, carbon monoxide poisoning, diabetic foot ulcers, and delayed radiation injury. Anti-aging and cognitive enhancement are not among them.

The main risks are ear and sinus barotrauma (the most common adverse effect), temporary myopia, oxygen toxicity seizures (rare, estimated around 1 in 10,000 sessions at standard pressures), and fire risk in oxygen-enriched environments. A 2024 review in Annals of African Medicine confirmed that hyperbaric therapy is safe when delivered by trained personnel following established protocols, with serious adverse events being uncommon.⁴

Johnson uses a clinical-grade hard chamber. Many consumers who follow his lead buy soft-shell portable chambers that operate near 1.3 ATA, well below the 2.0 ATA used in the longevity research. Those soft chambers cannot reproduce the pressures used in the published studies. Anyone considering HBOT for off-label purposes should consult a physician and seek treatment at a facility using hard-shell chambers with trained supervision. For home and clinic options, see our guides on hyperbaric chamber rental and what to know about DIY hyperbaric chambers.

Criticism and Skepticism

The scientific community has two distinct lines of criticism about HBOT’s emerging role in longevity and biohacking.

The first is methodological. The most-cited longevity studies come from a single group in Israel. The telomere study had no placebo control, a small sample (n=35), and measured blood cell biomarkers rather than clinical outcomes like disease incidence or lifespan. Telomere length in isolated blood cells is a surrogate marker, not a direct measure of health, and it is not known whether the observed changes translate to any meaningful clinical benefit.

The second is commercial. Johnson’s public profile drives significant traffic to companies selling HBOT equipment and sessions. His financial interests, documented or not, are worth factoring into how his endorsements are received. This is not unique to Johnson, it applies to all celebrity health advocates, but it is relevant context.

Broader Implications for Longevity Enthusiasts

The interest Johnson has generated has a useful side effect: it is pushing researchers to take longevity applications more seriously. Clinical trials on HBOT for aging, cognitive decline, and long COVID have expanded since 2020. The global HBOT market, estimated at roughly $4 billion in 2025 and projected to reach about $6.7 billion by 2034 according to market-research firm Precedence Research, is growing partly on the back of this expanding research agenda.

For the average person inspired by Johnson’s approach, the practical question is what an evidence-based path looks like. It means working with a physician, not copying a protocol from social media. It means using a hard-shell chamber at a clinic that reaches therapeutic pressures (1.5 to 2.4 ATA), not a soft portable unit. And it means tracking outcomes systematically, not relying on subjective self-report.

What This Means If You Are Considering HBOT

Johnson’s hyperbaric chamber use reflects genuine curiosity about an emerging area of clinical research. The underlying science, particularly the Efrati group’s RCTs on cognitive function, telomere biology, and physical performance in aging adults, is more developed than the biohacking framing suggests.

What it is not is proof. Johnson’s n=1 experience tells us nothing about what HBOT does for anyone else. The clinical evidence for anti-aging applications remains preliminary, limited to a single research group, and not FDA-approved. If you are inspired to explore HBOT, the path forward runs through a physician and a properly supervised clinical setting, not through celebrity mimicry.

Seph Fontane Pennock

Author

Seph Fontane Pennock is the founder of BaricBoost.com and Regenerated.com, a clinic directory for regenerative medicine serving 10,000+ providers across the United States. He previously built and sold PositivePsychology.com, which grew to 19 million users and became the largest evidence-based positive psychology resource on the web. Seph brings direct experience as an HBOT patient, having completed protocols at clinics across three continents while navigating mold illness, systemic inflammation, and autoimmune conditions. His treatment journey includes hyperbaric oxygen therapy, peptide protocols, NAD+ therapy, and consultations with specialists from Dubai to Cape Town to Mexico. This combination of entrepreneurial track record and lived patient experience shapes everything published on BaricBoost.com. Every article is grounded in peer-reviewed research, informed by real clinical encounters, and written for patients making high-stakes treatment decisions. Seph's focus is on bringing transparency, scientific rigor, and practical guidance to the hyperbaric oxygen therapy space.

Website